Recent Advances in Oligonucleotide Therapeutics in Oncology

DOI Web Site 2 Citations
  • Haoyu Xiong
    Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
  • Rakesh N. Veedu
    Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia
  • Sarah D. Diermeier
    Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand

Description

<jats:p>Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges.</jats:p>

Journal

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top